Epstein–Barr virus as a leading cause of multiple sclerosis: mechanisms and implications
Epidemiological studies have provided compelling evidence that multiple sclerosis (MS) is a
rare complication of infection with the Epstein–Barr virus (EBV), a herpesvirus that infects …
rare complication of infection with the Epstein–Barr virus (EBV), a herpesvirus that infects …
Modulation of regulatory T cell function and stability by co-inhibitory receptors
LE Lucca, M Dominguez-Villar - Nature Reviews Immunology, 2020 - nature.com
Regulatory T (Treg) cells constitute a dynamic population that is essential for controlling
immune responses in health and disease. Defects in Treg cell function and decreases in …
immune responses in health and disease. Defects in Treg cell function and decreases in …
Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance
E Raschi, M Gatti, F Gelsomino, A Ardizzoni… - Targeted Oncology, 2020 - Springer
The advent of immune checkpoint inhibitors (ICIs) caused a paradigm shift both in drug
development and clinical practice; however, by virtue of their mechanism of action, the …
development and clinical practice; however, by virtue of their mechanism of action, the …
Current targeted therapy for metastatic colorectal cancer
T Ohishi, MK Kaneko, Y Yoshida, A Takashima… - International journal of …, 2023 - mdpi.com
Colorectal cancer (CRC) is the third most common type of cancer and the second leading
cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or …
cause of cancer deaths worldwide. Surgery or surgery plus radiotherapy and/or …
Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy—review of the literature and future outlook
Immune checkpoint inhibitor (ICI) therapy has revolutionized the management of various
cancers with previously poor prognosis. Despite its great efficacy, the therapy is associated …
cancers with previously poor prognosis. Despite its great efficacy, the therapy is associated …
Neurologic complications of immune checkpoint inhibitors
AM Haugh, JC Probasco… - Expert opinion on drug …, 2020 - Taylor & Francis
Introduction: Immune checkpoint inhibitors (ICI) are associated with a wide spectrum of
neurologic immune-related adverse events (irAEs) including meningo-encephalitis …
neurologic immune-related adverse events (irAEs) including meningo-encephalitis …
Cognitive impairment after cancer treatment: mechanisms, clinical characterization, and management
B Fleming, P Edison, L Kenny - bmj, 2023 - bmj.com
Cognitive impairment is a debilitating side effect experienced by patients with cancer treated
with systemically administered anticancer therapies. With around 19.3 million new cases of …
with systemically administered anticancer therapies. With around 19.3 million new cases of …
Neurologic toxicity of immune checkpoint inhibitors: a review of literature
V Albarrán, J Chamorro, DI Rosero… - Frontiers in …, 2022 - frontiersin.org
Immune checkpoint inhibitors have entailed a change of paradigm in the management of
multiple malignant diseases and are acquiring a key role in an increasing number of clinical …
multiple malignant diseases and are acquiring a key role in an increasing number of clinical …
Central nervous system demyelination associated with immune checkpoint inhibitors: review of the literature
Immune checkpoint inhibitors (ICI) are a novel class of antineoplastic treatment that
enhances immunity against tumors. They are associated with immune adverse events, and …
enhances immunity against tumors. They are associated with immune adverse events, and …
Implication of the gut microbiome and microbial-derived metabolites in immune-related adverse events: emergence of novel biomarkers for cancer immunotherapy
Immune checkpoint inhibitors (ICIs) have changed how we think about tumor management.
Combinations of anti-programmed death ligand-1 (PD-L1) immunotherapy have become the …
Combinations of anti-programmed death ligand-1 (PD-L1) immunotherapy have become the …